27 articles for AB Miller
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
43
2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists.
Syntex Research
19
Thiol-based angiotensin-converting enzyme 2 inhibitors: P1 modifications for the exploration of the S1 subsite.
Glaxosmithkline
15
Conformationally constrained farnesoid X receptor (FXR) agonists: alternative replacements of the stilbene.
Glaxosmithkline
25
Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.
Glaxosmithkline
23
FXR agonist activity of conformationally constrained analogs of GW 4064.
Glaxosmithkline
40
Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064.
Glaxosmithkline
12
Synthesis of 3-alkyl naphthalenes as novel estrogen receptor ligands.
Glaxosmithkline
24
Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite.
Glaxosmithkline
28
Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.
Glaxosmithkline
41
Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?
Glaxosmithkline
11
Ketoheterocycle-based inhibitors of cathepsin K: a novel entry into the synthesis of peptidic ketoheterocycles.
Glaxosmithkline
18
P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K.
Glaxosmithkline
10
A structural screening approach to ketoamide-based inhibitors of cathepsin K.
Glaxosmithkline
32
Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K.
Glaxosmithkline
17
Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions.
Glaxosmithkline
40
Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
Glaxosmithkline
42
Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP).
Glaxosmithkline
36
Bicyclic heteroaryl derivatives as CFTR potentiators
Cystic Fibrosis Foundation Therapeutics